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Background: Reduced DNA repair capacities due to inherited polymorphisms may increase the susceptibility to
cancers including gastric cancer. Previous studies investigating the association between Xeroderma Pigmentosum
group C (XPC) gene polymorphisms and gastric cancer risk reported inconsistent results. We performed a meta-analysis
to summarize the possible association.
Methods: All studies published up to January 2014 on the association between XPC polymorphisms and gastric cancer
risk were identified by searching electronic databases PubMed, EMBASE, Cochrane library, and Chinese Biomedical
Literature database (CBM). The association between XPC polymorphisms and gastric cancer risk was assessed by odds
ratios (ORs) together with their 95% confidence intervals (CIs).
Results: Six studies with 1,355 gastric cancer cases and 2,573 controls were finally included in the meta-analysis. With
respect to Lys939Gln polymorphism, we did not observe a significant association when all studies were pooled into
the meta-analysis. When stratified by ethnicity, source of control, and study quality, statistical significant association
was not detected in all subgroups. With respect to Ala499Val and PAT−/+polymorphisms, we also did not observe
any significant association with gastric cancer risk in the pooled analysis.
Conclusions: This meta-analysis based on current evidences suggested that the XPC polymorphisms (Lys939Gln,
Val499Arg, and PAT−/+) did not contribute to gastric cancer risk. Considering the limited sample size and ethnicity
included in the meta-analysis, further larger scaled and well-designed studies are needed to confirm our results.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1485880312555069
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Gastric cancer is one of the most common cancers and
cancer related deaths are highly prevalent worldwide [1].
The development of gastric cancer is a multifactorial
and multistep process. Previous epidemiological investi-
gations have identified that high consumption of salty
food, low consumption of fresh fruits and vegetables,
smoking, drinking, and Helicobacter pylori infection
were the major contributors to the development and
progression of gastric cancer [2-4]. However, most indi-
viduals exposed to these environmental risk factors
never develop gastric cancer while many gastric cancer* Correspondence: qinxue919@126.com
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unless otherwise stated.cases develop among individuals without those envir-
onmental factors, suggesting that other factors such
as genetic factors also play important roles in gastric
carcinogenesis.
The DNA repairing system, which was composed of
many DNA repair genes, plays an important role in
removing damaged genes, maintaining the genomic in-
tegrity and preventing carcinogenesis. The xeroderma
pigmentosum complementation group C (XPC) is one of
the eight core genes (i.e., ERCC1, XPA, XPB, XPC, XPD,
XPE, XPF, and XPG) in the nuclear excision repair
(NER) pathway of the DNA repairing system. XPC binds
to HR23B and forms the XPC-HR23B complex, which is
involved in the DNA damage recognition and DNA re-
pair initiation in the NER pathway [5-7], and the binding
of XPC to damaged DNA is the rate-limiting step fortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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acid protein, spans 33 kb on chromosome 3p25 and con-
tains 16 exons and 15 introns [9]. There are at least 687
reported single nucleotide polymorphisms (SNPs) in the
XPC gene region (http://www.ncbi.nlm.nih.gov/projects/
SNP). Among all the identified SNPs, three common
polymorphisms have been extensively studied: (a) a sub-
stitution of alanine for valine in codon 499 (Ala499Val,
rs2228000), in the interaction domain of XPC with
hHRAD23; (b) an A to C transversion in exon 15 result-
ing in a lysine-to-glutamine transition at position 939
(Lys939Gln, rs2228001), located in the interaction do-
main with TFIIH; and (c) a poly AT region on intron 9
(PAT−/+). It was reported that the variant alleles of the
three polymorphisms in the XPC genes correlated with
relatively high DNA adduct levels in lymphocyte DNA,
indicating that these polymorphisms were associated
with decreased DNA repair capacity [10,11]. Therefore,
it was biologically reasonable to hypothesize a potential
relationship between the XPC gene polymorphisms and
cancer susceptibility.
To date, the XPC gene polymorphisms (Lys939Gln,
Val499Arg, and PAT−/+) to gastric cancer risk have
been a research focus in scientific community and have
drawn increasing attention. Several original studies have
reported the role of XPC polymorphisms in gastric can-
cer risk [12-17], but the results are inconclusive. For
genetic association studies that investigate candidate
polymorphisms, sample size is an important influencing
factor for study accuracy. Small sample size might have
inadequate power to explore a true association of mod-
est effect [18], especially for complex multifactorial dis-
ease such as gastric cancer. While combining data from
all eligible studies by meta-analysis has the advantage of
increasing statistical power and reducing random error
and obtaining precise estimates for some potential gen-
etic associations. Therefore, in this study, we conducted
a quantitative meta-analysis including all eligible studies.
Methods
Search strategy
We conducted a comprehensive literature search in
PubMed, EMBASE, Cochrane library, and Chinese Bio-
medical Literature (CBM) databases up to January 01, 2014
using the following search strategy: (“gastric cancer”) and
(“xeroderma pigmentosum complementation group C”, or
“XPC”). There was no restriction on time period, sample
size, population, language, or type of report. All eligible
studies were retrieved and their references were checked
for other relevant studies. The literature retrieval was per-
formed in duplication by two authors independently (Qiliu
Peng and Yu Lu). When multiple publications reported on
the same or overlapping data, we chose the most recent or
largest population.Inclusion and exclusion criteria
Studies were considered if they met the following inclu-
sion criteria: (1) case–control or cohort studies which
evaluated the association between XPC polymorphisms
and gastric cancer; (2) had an odds ratio (OR) with 95%
confidence interval (CI) or other available data for esti-
mating OR (95% CI); and (3) the control population did
not contain malignant tumor patients. Studies were ex-
cluded if one of the following existed: (1) no control
population; (2) duplicate of previous publication; and
(3) insufficient information for data extraction.
Data extraction
Information was extracted by two authors independently
according to the inclusion criteria listed above. Data ex-
tracted from eligible studies included the first author,
publication year, ethnicity, country, genotyping methods,
matching criteria, source of control, gastric cancer ascer-
tainment, total numbers of cases and controls and geno-
type frequencies of cases and controls. Ethnic backgrounds
were categorized as Caucasian, Asian. To ensure the accur-
acy of the information extracted, the two authors checked
the data extraction results and reached consensus on all of
the items. If different results generated, they would check
the data again and have a discussion to come to an agree-
ment. If these two authors could not reach a consensus,
another author (Xue Qin) was consulted to resolve the
dispute.
Quality score assessment
The quality of eligible studies was assessed independ-
ently by two authors (Qiliu Peng and Xianjun Lao) ac-
cording to a set of predefined criteria (Table 1) modified
from our previous meta-analysis of molecular associ-
ation study [19]. The revised criteria cover the repre-
sentativeness of cases, source of controls, ascertainment
of gastric cancer, total sample size, quality control of
genotyping methods, and Hardy-Weinberg equilibrium
(HWE) in the control population. Disagreements were
resolved by consensus. Total scores ranged from 0
(lowest) to 10 (highest). Articles with scores equal to
or higher than 7 were considered “high-quality” studies,
whereas those with scores less than 7 were considered
“low-quality” studies.
Statistical analysis
Crude odds ratios (ORs) with their 95% confidence in-
tervals (CIs) were used to assess the strength of associ-
ation between the XPC polymorphisms and gastric
cancer risk. The pooled ORs were performed for co-
dominant genetic models, dominant genetic model, and re-
cessive genetic model, respectively. Heterogeneity among
studies was checked by the chi-square-based Q-test and I2
statistics [20,21]. If the result of the heterogeneity test was
Table 1 Scale for quality assessment
Criteria Score
Representativeness of cases
Selected from cancer registry or multiple cancer center sites 2
Selected from oncology department or cancer institute 1




Population or community based 2
Both population-based and hospital-based/healthy volunteers/
blood donors
1.5
Hospital-based controls without gastric cancer 1
Cancer-free controls without total description 0.5
Not described 0
Ascertainment of gastric cancer
Histologically or pathologically confirmed 2






Quality control of genotyping methods





Hardy-Weinberg equilibrium in controls 1
Hardy-Weinberg disequilibrium in controls 0.5
No checking for Hardy-Weinberg disequilibrium 0
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2 ≥ 50%, indicating the presence of het-
erogeneity, a random-effects model (the DerSimonian
and Laird method) was used to estimate the sum-
mary ORs [22]; otherwise, when the result of the het-
erogeneity test was PQ ≥ 0.1 and I
2 < 50%, indicating the
absence of heterogeneity, the fixed-effects model (the
Mantel–Haenszel method) was used [23]. Subgroup ana-
lyses were performed according to ethnicity, source of
control, and study quality. Sensitivity analysis was con-
ducted by sequential omission of individual study to as-
sess the robustness of the results. Publication bias was
assessed using a Begg’s funnel plot and Egger’s regression
asymmetry test [24]. If publication bias existed, the Duval
and Tweedie non-parametric “trim and fill” method was
used to adjust for it [25]. The distribution of the geno-
types in the control population was tested for HWE using
a goodness-of-fit Chi-square test. All the statistical tests
were performed using Stata software, version 12.0 (Stata
Corp., College Station, TX).Results
Eligible studies
Based on the search criteria, seven potential relevant
studies were identified. One of these articles was ex-
cluded because it contained overlapping data [26]. Man-
ual search of references cited in the published studies
did not reveal any additional articles. As a result, a total
of six studies met the inclusion criteria were included in
the meta-analysis [12-17]. The main characteristics of
the eligible studies were presented in Table 2. Among
them, five studies [12,14-17] including 1,049 cases and
2,026 controls were available for Lys939Gln polymorph-
ism, three studies [14,15,17] with 817 cases and 1438
controls for Val499Arg polymorphism, and two studies
[13,15] containing 559 cases and 1159 controls for
PAT−/+polymorphism. The sample size of these studies
varied considerably, ranging from 222 to 977 individ-
uals. Of all the eligible studies, two were conducted in
Caucasians [12,16] and three were in Asians [14,15,17]
for Lys939Gln polymorphism; all the three eligible stud-
ies for Val499Arg polymorphism were conducted in
Asians [14,15,17]; one was conducted in Caucasians [13]
and one [15] was in Asians for PAT−/+polymorphism.
Three studies were population–based and three were
hospital–based studies. One study in the present meta-
analysis did not provide definite criteria for the CRC as-
certainment [12]. Two genotyping methods were used,
including PCR-RFLP and TaqMan assay. The genotype
distributions of the controls were consistent with HWE
in all of the included studies.
Quantitative analysis
XPC Lys939Gln
The main results of meta-analysis of XPC Lys939Gln
polymorphism and gastric cancer risk were present in
Table 3. There was no evidence of significant association
between XPC Lys939Gln polymorphism and gastric
cancer risk when all the eligible studies were pooled
into the meta-analysis (Gln/Gln vs. Lys/lys: OR = 1.123,
95% CI = 0.881–1.431, P = 0.349; Gln/Lys vs. Lys/lys:
OR = 1.083, 95% CI = 0.917–1.277, P = 0.347; Gln/Gln +
Gln/Lys vs. Lys/lys: OR = 1.092, 95% CI = 0.933–1.277,
P = 0.273, Figure 1; Gln/Gln vs. Gln/Lys + Lys/lys: OR =
1.046, 95% CI = 0.838-1.307, P = 0.691). In subgroup ana-
lyses stratified by ethnicity, source of control, and study
quality, statistically significant association was also not ob-
served in all subgroups. Meanwhile, no significant hetero-
geneity was found in the pooled analysis and subgroup
analyses (PQ Values <0.1 and I
2 > 50%).
XPC Val499Arg
The main results of meta-analysis of XPC Val499Arg
polymorphism and gastric cancer risk were summarized
in Table 3. We did not found any significant association
Table 2 Characteristics of studies included in the meta-analysis
First author
(Year)








SNPs HWE(P value) Quality
scoresLys939Gln Ala499Val PAT+/−
Palli 2010 Italy Caucasian 306/547 TaqMan Gender PB Histo- PAT+/− — — 0.085 7
Dong 2008 China Asian 253/612 PCR-RFLP Age and gender PB Histopatho- Lys939Gln, Ala499Val,
PAT+/−
0.699 0.217 0.786 8.5
Engin 2011 Turkey Caucasian 106/116 PCR-RFLP Age and BMI HB NR Lys939Gln 0.642 — — 4.5
Long 2010 China Asian 361/616 TaqMan Age, gender, ethnicity,
smoking, and drinking
HB Histopatho- Lys939Gln, Ala499Val 0.446 0.673 — 6
Ye 2006 Sweden Caucasian 126/472 PCR-RFLP NR PB Histo- Lys939Gln 0.540 — — 7
Li 2010 China Asian 203/210 PCR-RFLP Age, gender, smoking,
and drinking
HB Patho- Lys939Gln, Ala499Val 0.173 0.462 — 7.5
GC, Gastric cancer; Histopatho-, Histopathologically confirmed; Histo-, Histologically confirmed; Patho-, Pathologically confirmed; NR, Not reported; PB, Population–based; HB, Hospital–based; HWE, Hardy–Weinberg















Table 3 Meta-analysis of the XPC polymorphisms and gastric cancer risk
Comparison Population No. of
studies
Test of association Mode Test of heterogeneity
OR 95% CI P Value χ2 PQ Value I
2
Lys939Gln
Gln/Gln vs. Lys/lys Overall 5 1.123 0.881-1.431 0.349 F 2.69 0.612 0.0
Caucasian 2 1.016 0.490-2.109 0.965 F 2.31 0.128 46.8
Asian 3 1.140 0.857-1.516 0.368 F 0.34 0.843 0.0
PB 2 1.260 0.877-1.810 0.212 F 0.24 0.623 0.0
HB 3 1.026 0.741-1.420 0.879 F 1.76 0.414 0.0
High quality 3 1.179 0.860-1.616 0.308 F 0.75 0.686 0.0
Low quality 2 1.048 0.718-1.530 0.807 F 1.71 0.191 41.6
Gln/Lys vs. Lys/lys Overall 5 1.083 0.917-1.277 0.347 F 1.21 0.876 0.0
Caucasian 2 0.993 0.689-1.432 0.972 F 0.87 0.352 0.0
Asian 3 1.107 0.919-1.332 0.284 F 0.08 0.962 0.0
PB 2 1.026 0.795-1.324 0.846 F 0.64 0.424 0.0
HB 3 1.126 0.906-1.400 0.285 F 0.27 0.872 0.0
High quality 3 1.062 0.855-1.319 0.587 F 0.90 0.639 0.0
Low quality 2 1.112 0.861-1.437 0.417 F 0.24 0.628 0.0
Gln/Gln + Gln/Lys vs. Lys/lys Overall 5 1.092 0.933-1.277 0.273 F 0.24 0.994 0.0
Caucasian 2 1.015 0.720-1.430 0.933 F 0.01 0.906 0.0
Asian 3 1.113 0.933-1.327 0.235 F 0.00 0.998 0.0
PB 2 1.076 0.846-1.369 0.551 F 0.18 0.667 0.0
HB 3 1.103 0.897-1.356 0.351 F 0.03 0.986 0.0
High quality 3 1.087 0.886-1.333 0.424 F 0.21 0.900 0.0
Low quality 2 1.098 0.860-1.401 0.453 F 0.02 0.881 0.0
Gln/Gln vs. Gln/Lys + Lys/lys Overall 5 1.046 0.838-1.307 0.691 F 6.57 0.160 39.2
Caucasian 2 0.921 0.344-2.468 0.870 F 5.98 0.114 43.3
Asian 3 1.083 0.829-1.417 0.558 F 0.47 0.791 0.0
PB 2 1.253 0.896-1.751 0.187 F 0.77 0.381 0.0
HB 3 0.914 0.680-1.229 0.552 F 3.90 0.142 48.8
High quality 3 1.157 0.862-1.553 0.331 F 1.66 0.435 0.0
Low quality 2 0.828 0.400-1.712 0.610 F 3.90 0.148 44.3
Ala499Val
Val/Val vs. Ala/Ala Asian 3 0.861 0.632-1.172 0.341 F 0.57 0.754 0.0
Val/Ala vs. Ala/Ala Asian 3 0.815 0.611-1.089 0.167 F 4.72 0.194 37.6
Val/Val + Val/Ala vs. Ala/Ala Asian 3 0.823 0.630-1.076 0.155 F 4.49 0.106 35.5
Val/Val vs. Val/Ala + Ala/Ala Asian 3 0.947 0.703-1.274 0.717 F 0.04 0.981 0.0
PAT−/+
+/+vs. −/− Overall 2 1.035 0.763-1.404 0.825 F 0.12 0.726 0.0
+/− vs. −/− Overall 2 0.855 0.681-1.073 0.176 F 0.00 0.975 0.0
(+/+) + (+/−) vs. (−/−) Overall 2 0.896 0.724-1.111 0.317 F 0.05 0.830 0.0
(+/+) vs. (+/−) + (−/−) Overall 2 1.141 0.871-1.495 0.338 F 0.20 0.652 0.0
OR, odds ratio; CI, confidence intervals; R, random effects model; F, fixed effects model; PB, Population–based; HB, Hospital–based.
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cer risk when all the eligible studies were pooled into
the meta-analysis (Val/Val vs. Ala/Ala: OR = 0.861, 95%CI = 0.632–1.172, P = 0.341; Val/Ala vs. Ala/Ala: OR =
0.815, 95% CI = 0.611–1.089, P = 0.167; Val/Val + Val/Ala
vs. Ala/Ala: OR = 0.823, 95% CI = 0.630–1.076, P = 0.155;
Figure 1 Forest plot of subgroup analysis by ethnicity on the association between XPC Lys939Gln polymorphism and gastric cancer
risk using a fixed-effect model (dominant model Gln/Gln + Gln/Lys vs. Lys/lys).
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1.274, P = 0.717). In addition, no significant heterogeneity
was found in the pooled analysis (PQ Values <0.1 and
I2 > 50%). We did not perform subgroup analysis because
of the limited number of studies available for XPC
Val499Arg polymorphism.
XPC PAT−/+
The results of meta-analysis of XPC PAT−/+polymorph-
ism and gastric cancer risk were summarized in Table 3.
Overall, there were no significant associations of XPC
PAT−/+polymorphism and gastric cancer risk when
all the eligible studies were pooled into the meta-
analysis (+/+vs. −/−: OR = 1.035, 95% CI = 0.763–1.404,
P = 0.825; +/− vs. −/−: OR = 0.855, 95% CI = 0.681–1.073,
P = 0.176; (+/+) + (+/−) vs. (−/−): OR = 0.896, 95% CI =
0.724–1.111, P = 0.317; (+/+) vs. (+/−) + (−/−): OR =
1.141, 95% CI = 0.871-1.495, P = 0.338). Moreover, statis-
tical significant heterogeneity was also not found in the
pooled analysis. We also did not perform subgroup ana-
lysis because only two studies were available for XPC
PAT−/+polymorphism.
Sensitivity analysis
A single study involved in the meta-analysis was deleted
each time to reflect the influence of the individual data-
set to the pooled OR, and the corresponding pooled OR
was not materially altered (Figure 2), indicating that our
results were statistically robust.
Publication bias
Begger’s funnel plot and Egger’s test were performed to
assess the publication bias of the included studies forXPC Lys939Gln and XPC Val499Arg polymorphisms.
The shape of the funnel plot did not reveal any evidence
of obvious asymmetry. Then, the Egger’s test was used
to provide statistical evidence of funnel plot symmetry.
The results still did not suggest any evidence of publica-
tion bias for XPC Lys939Gln (P = 0.152 for Gln/Gln vs.
Lys/lys; P = 0.778 for Gln/Lys vs. Lys/lys; P = 0.339 for
Gln/Gln + Gln/Lys vs. Lys/lys; P = 0.282 for Gln/Gln vs.
Gln/Lys + Lys/lys) and XPC Val499Arg (P = 0.948 for
Val/Val vs. Ala/Ala; P = 0.959 for Val/Ala vs. Ala/Ala;
P = 0.937 for Val/Val + Val/Ala vs. Ala/Ala; P = 0.852
for Val/Val vs. Val/Ala +Ala/Ala). We did not carry out
Begger’s funnel plot and Egger’s test for XPC PAT−/+poly-
morphism because only two studies were available for this
polymorphism.
Discussion
Previous studies evaluating the association between XPC
polymorphisms (Lys939Gln, Val499Arg, and PAT−/+)
and gastric cancer risk have provided inconsistent re-
sults, and most of these studies involved no more than a
few hundred gastric cancer cases, which is too few to as-
sess any genetic effects reliably. Meta-analysis has been
recognized as an important way to detect the effect of
selected genetic polymorphisms on disease risk precisely
and to identify potential important sources of between-
study heterogeneity. Hence, we performed this meta-
analysis including all published studies to investigate the
association between the XPC polymorphisms and gastric
cancer risk. To the best of our knowledge, this is the
first comprehensive meta-analysis of genetics studies
on the association between XPC polymorphisms and
gastric cancer risk. Our results suggested that the XPC
Figure 2 Sensitivity analysis for XPC Lys939Gln polymorphism and gastric cancer risk (dominant model Gln/Gln + Gln/Lys vs. Lys/lys).
This figure shows the influence of individual studies on the summary OR. The middle vertical axis indicates the overall OR and the two vertical
axes indicate its 95% CI. Every hollow round indicates the pooled OR when the left study is omitted in this meta-analysis. The two ends of every
broken line represent the 95% CI.
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not associated with gastric cancer risk when all studies
were pooled together. In subgroup analyses stratified by
ethnicity, source of control, and study quality, statis-
tical significant association was also not observed in all
subgroups.
DNA repair mechanisms are important pathways in
the removal of DNA adducts from damaged genomic
sites and play crucial roles in the carcinogenesis of can-
cers [27]. XPC is a key member of the NER pathway. It
binds to HR23B and forms the stable XPC-HR23B com-
plex and is involved in the recognition and initiation of
the genome repair of the NER pathway [5-7]. Mutations
of the XPC genes may increase gastric cancer suscepti-
bility by causing a severe depression of NER and conse-
quently altering DNA repair activity [28]. However, in
our study, no significant association between variant ge-
notypes of XPC polymorphisms and gastric cancer risk
was observed in the pooled analysis and subgroup ana-
lyses, which was inconsistent with the hypothesis above.
Several potential concerns should be discussed for the
non-significant associations between XPC polymorphisms
and gastric cancer susceptibility. First, gastric cancer is a
multi-factorial disease resulting from complex interactions
between environmental and genetic factors [29,30]. It is
possible that the variants at this locus have some modest
effects on gastric cancer. Environmental factors, such as
living habits and exposure to carcinogens, however, may
also play a role in gastric cancer development. Thus, no
regard of these factors may confer the non-significance for
the independent role of XPC polymorphisms in gastric
cancer development. Second, there are eight core genes(i.e., ERCC1, XPA, XPB, XPC, XPD, XPE, XPF, and XPG)
in the NER pathway of the DNA repairing system, variants
in these genes may interfere with each other in associated
functions. This could cover the true associations of XPC
gene polymorphisms with gastric cancer. Therefore, other
variants as gastric cancer risk factors should be induced as
co-variants to determine their true effects. The lack of
considering above confounding factors might affect the
significance of their results. Moreover, the null result may
be due to the limited number of studies included in the
meta-analysis, which had insufficient statistical power to
detect a slight effect or may have generated a fluctuated
risk estimate. Therefore, the negative results of the associ-
ation between XPC polymorphisms and gastric cancer risk
should be interpreted with caution.
Some limitations of this meta-analysis should be ac-
knowledged. First, only published studies were included
in the meta-analysis. It is possible that some related un-
published studies that might meet the inclusion criteria
were missed; therefore, publication bias may have been
present, even though statistical analysis indicated this
not to be the case. Second, our results were based on
unadjusted estimates and a more precise analysis could
be conducted if more individual data were available; this
would allow for adjustment by other covariates such as
the quantity of salty food consumption, drinking, smoking
and Helicobacter pylori infection; Third, in the pooled ana-
lyses for XPC Val499Arg and XPC PAT−/+polymorphisms,
the number of studies included was relatively small, not
having enough statistical power to investigate a real associ-
ation of the polymorphisms with gastric cancer susceptibil-
ity. However, our meta-analysis also had some advantages.
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pooled from different studies, which significantly increased
the statistical power compared with the individual studies.
Second, no heterogeneity and publication bias was de-
tected in our meta-analysis, indicating that the pooled
results were precise and reliable.
Conclusions
In conclusion, the result of this meta-analysis based on
current evidences suggests that the XPC polymorphisms
(Lys939Gln, Val499Arg, and PAT−/+) may not contribute
to gastric cancer risk. However, it is necessary to conduct
large sample studies using standardized unbiased genotyp-
ing methods, homogeneous gastric cancer patients, and
well-matched controls. Moreover, gene–gene and gene–
environment interactions should also be considered in the
analysis. Such studies taking these factors into account
may eventually lead to our better, comprehensive under-
standing of the association between the XPC polymor-
phisms and gastric cancer risk.
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